IGM Biosciences Leaders to Share Insights at Stifel’s Virtual Summit
IGM Biosciences, Inc. (NASDAQ: IGMS), a clinical-stage biotechnology company focused on antibody-based medicines, will take part in the Stifel 2024 Virtual Immunology and Inflammation Summit. Chief Executive Officer Fred Schwarzer and Head of Research & Autoimmunity Mary Beth Harler, M.D., will join a fireside chat—an open conversation rather than a formal presentation—on September 17 at 9:00 a.m. EDT. The discussion will spotlight how the company is advancing engineered IgM antibodies and where leadership sees the field heading next.
What to Expect from the Session
The summit convenes researchers, executives, and investors to examine current thinking in immunology and inflammation. IGM’s participation underscores the company’s focus on serious diseases where new approaches are still needed. During the conversation, Schwarzer and Harler plan to cover IGM’s strategy, how the team prioritizes programs, and the potential of engineered IgM antibodies in hard-to-treat conditions. Expect a clear view into the company’s direction as well as the principles guiding its research—what they’re building, why it matters, and how they’re measuring progress.
How to Watch the Live Conversation
A live webcast will be available on the company’s website in the “Events and Presentations” section. If you can’t tune in at 9:00 a.m. EDT on September 17, an archived replay will remain accessible for 90 days after the event. That window gives you time to watch the full discussion and revisit specific points that stand out.
About IGM Biosciences and Its IgM Platform
IGM Biosciences develops a distinct class of antibody medicines. Traditional IgG antibodies have two binding sites; IGM’s engineered IgM antibodies have ten. That multivalent design is intended to provide a different toolkit for tackling cancer, autoimmune disorders, and inflammatory diseases. While the company is still in the clinic, the goal is straightforward: use the unique architecture of IgM antibodies to engage biological targets in ways that standard approaches may not.
Putting it simply, more binding sites can translate to a different way of interacting with targets—another lever for scientists to pull as they design therapies. IGM’s work centers on turning that design into medicines that can be tested, refined, and, if successful, brought to patients.
Key Collaboration
IGM Biosciences has a strategic global partnership with Sanofi focused on developing and commercializing IgM antibody agonists in immunology and inflammation. The collaboration combines IGM’s IgM platform with Sanofi’s development and commercial capabilities. The aim is to accelerate programs that could expand treatment options across areas where immune pathways play a central role.
Contacting IGM Biosciences
For additional details on IGM’s plans, programs, or appearance at the summit, please reach out through the company’s listed contacts. Argot Partners represents IGM for external communications. Media or investor inquiries can be directed to David Pitts at the number provided. A brief conversation with the team can help clarify focus areas, timing, and how to follow future updates.
Frequently Asked Questions
When and where is IGM’s session taking place?
The fireside chat with CEO Fred Schwarzer and Mary Beth Harler, M.D., is part of the Stifel 2024 Virtual Immunology and Inflammation Summit on September 17 at 9:00 a.m. EDT. It’s a virtual event.
What topics will the speakers cover?
They plan to discuss IGM’s strategy, the company’s progress with engineered IgM antibodies, and how those medicines could address cancer, autoimmune disorders, and inflammatory diseases.
How do I access the webcast and replay?
Go to IGM’s website and open the “Events and Presentations” section to stream the live session. A replay will be available in the same location for 90 days after the event.
Why focus on IgM antibodies instead of IgG?
IgM antibodies have ten binding sites, compared with two for IgG. That design difference offers a distinct way to engage targets and may provide advantages in certain therapeutic settings.
What does the Sanofi partnership involve?
IGM and Sanofi are working together to develop and commercialize IgM antibody agonists in immunology and inflammation, pairing IGM’s platform with Sanofi’s development and commercial reach.
